Emerald Health Sciences Inc. - 10 Nov 2022 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Reporting relationship: 10%+ Owner
Issuer ticker: SKYE
Reported as of: 10 Nov 2022
Net transaction value: +$1,880,141
SEC form: 4
Accepted by SEC: 17 Mar 2023, 14:52:02 UTC
Prior SEC filing: 31 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Stephen Hall, CFO of Emerald Health Sciences Inc.

Key filing fact

Emerald Health Sciences Inc. filed Form 4 for Skye Bioscience, Inc. (SKYE) on 17 Mar 2023.

Key facts

This page summarizes Emerald Health Sciences Inc.'s Form 4 filing for Skye Bioscience, Inc. (SKYE).
7 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 17 Mar 2023, 14:52.

Change

Previous filing in this sequence was filed on 31 Jan 2022.
Current net transaction value: +$1,880,141.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SKYE transaction

Common Stock

Award

Transaction value: $282,905
Shares: +16,641,486
Change %: +15%
Price: $0.0170
Shares after: 128,028,737
Date: 22 Feb 2023
Ownership: Direct

SKYE transaction

Common Stock

Award

Transaction value: $1,597,236
Shares: +41,379,164
Change %: +32%
Price: $0.0386
Shares after: 169,407,901
Date: 22 Feb 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SKYE transaction Derivative

Warrants

Other

Transaction value: $0
Shares: +9,141,486
Change %
Price: $0.000000
Shares after: 9,141,486
Date: 10 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,141,486
Exercise price: $0.1510
Footnotes: F1

SKYE transaction Derivative

Warrants

Disposed to Issuer

Transaction value: $0
Shares: -9,141,486
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 22 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,141,486
Exercise price: $0.0170

SKYE transaction Derivative

Warrants with Credit Facility of Oct 5, 2018

Purchase

Transaction value: $0
Shares: -2,500,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 22 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500,000
Exercise price: $0.0386

SKYE transaction Derivative

Warrants with Credit Facility of Oct 5, 2018 - T2

Disposed to Issuer

Transaction value: $0
Shares: -2,500,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 22 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500,000
Exercise price: $0.0386
Footnotes: F2

SKYE transaction Derivative

Warrants with Credit Facility of Oct 5, 2018 - T3

Disposed to Issuer

Transaction value: $0
Shares: -2,500,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 22 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500,000
Exercise price: $0.0386
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Warrants were acquired pursuant to a merger between Issuer and Emerald Health Therapeutics, Inc. ("Emerald"), whereby Reporting Person's outstanding warrants to purchase Emerald common stock were exchanged for warrants to purchase Issuer common stock.

Footnote F2

Aggregate exercise price for the warrants was paid through a reduction in the debt Issuer owed to Reporting Person under the Multi Draw Credit Facility.